October 4, 2016
The American Association for the Study of Liver Diseases (AASLD) is the premier U.S. liver research organization. The AASLD engages in many activities, including holding conferences and providing advice for physicians caring for patients with liver disease caused by viral hepatitis, particularly hepatitis B virus (HBV) and hepatitis C virus (HCV). The AASLD also produces guidelines for the screening, care and treatment of people with viral hepatitis in cooperation with another organization, the Infectious Diseases Society of America (IDSA).
In the past several years, all-oral regimens called direct-acting antivirals (DAAs) have been approved in Canada, the U.S. and other high-income countries for the treatment of people with HCV. Overall, these regimens are highly effective, well tolerated and used for a shorter period of time than older therapy (a combination of interferon and ribavirin). As a result, more people are being treated for chronic HCV infection.
Some people who are infected with HCV are also co-infected with other viruses such as HBV and HIV. Both HCV and HBV infect the liver and can cause serious liver injury if left untreated. Sometimes when people co-infected with HCV and HBV are treated with DAAs but not also treated for HBV, their hepatitis B virus can flare up or reactivate -- infecting more liver cells which in turn produce more copies of HBV. This rise in HBV can cause liver injury.
In September 2016, the AASLD-IDSA's committee tasked with drafting treatment guidelines (called the Guidelines Panel) issued a press release about HCV treatment and HBV screening, stating the following:
"All patients beginning HCV treatment using DAA therapies should be assessed for HBV."
Raymond Chung, M.D., co-chair of the Panel, said that "cases of HBV reactivation during or after DAA therapy for HCV have been reported in HBV/HCV co-infected patients who were not already on HBV suppressive therapy." He added, "The severity of these cases has ranged from mild to severe liver injury that can be life threatening. While we do not know how frequently this occurs, the Panel recommends HBV testing for all patients beginning DAA treatment for HCV."
Furthermore, the Panel made the following recommendations:
Panel co-chair Susanna Naggie, M.D., M.H.S., noted: "While there currently isn't enough data to make clear recommendations for patients who have been exposed to HBV and resolved the virus, whether spontaneous or after antiviral therapy, we recommend these patients be monitored for HBV reactivation. This is particularly important in the event of unexplained increases in liver enzymes and during and/or after completion of DAA therapy."
For more information about AASLD-IDSA's recommendations for the testing, care and treatment of people with HCV go to www.hcvguidelines.org/.
AASLD. People with hepatitis C should be tested for hepatitis B before starting antiviral therapy. Press release. 16 September 2016. Available at: www.aasld.org/about-aasld/pressroom/people-hepatitis-c-should-be-tested-hepatitis-b-starting-antiviral-therapies
|Understanding the Magnitude of the Viral Hepatitis Epidemics in the United States|
|New HBV Drugs and Non-Viral Liver Disease in HIV-Positive People|
|Report Concludes Elimination of Hepatitis B and C in U.S. Feasible|
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade|
|CROI 2018: Highlights and What's Next for Advocates|
|Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence|
|Injection Drug Use Among People Living With HIV: A Missed Opportunity to Save Lives|
|Statin Use Might Reduce Risk of Cancer in HIV-Positive People|
|Insurers and Pharmas Must Help Fix HIV Drug Pricing System, Advocates Say|